Dexamethasone and COVID-19 Inpatient Mortality
Completed
Conditions studied: Coronavirus
In brief
The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.
Key facts
- Study ID
- NCT04926571
- Run by
- Aetion, Inc.
- People needed
- 14105
- Starts
- 2020-04-01
- Expected to finish
- 2021-08-27
- Last updated by the study team
- 2023-04-18
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Hospitalized Patients with confirmed COVID-19 (diagnosis of U07.1 or positive or presumptive positive SARS-CoV-2 diagnostic laboratory test result) occurring between 21 days prior to the hospital admission date and the treatment index date.
You may not qualify if…
- No interaction with the healthcare system (medical encounter) in the 183 days prior to and including hospital admission (Day -183 to Day 0) to minimize the potential for misclassification of baseline covariates and/or new use
- No age or sex recorded in the 183 days prior to and including hospital admission (Day -183 to Day 0) as required for matching
- No geographic region recorded in 183 days prior to and including hospital admission (Day -183 to Day 0) as necessary to adjust for regional variation
- Any recorded use of any CSI (dispensing or remaining supply) in the 90-day washout prior to the treatment index date (Day T-90 to Day T-1) to satisfy new use definition
- Any record of a COVID-19 vaccine recorded on or any time prior to the treatment index date given that these patients are assumed to be selectively different (Day S to Day T)
Where it is running
- Aetion, Inc. — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.